Assertio Holdings (ASRT) Other Accumulated Expenses (2019 - 2026)
Assertio Holdings' (ASRT) quarterly Other Accumulated Expenses came in at $4.8 million in Q1 2026, down 69.81% year-on-year from $16.0 million in Q1 2025, and little changed quarter-over-quarter from $4.9 million in Q4 2025.
Assertio Holdings (ASRT) Other Accumulated Expenses (2019 - 2026) Analysis & Trends
Assertio Holdings has disclosed Other Accumulated Expenses across 8 years of filings, most recently posting $4.8 million for Q1 2026.
- Other Accumulated Expenses for Q1 2026 came in at $4.8 million, down 69.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.8 million (down 69.81% YoY), and the FY2025 annual result was $4.9 million, up 19.04% from the prior year.
- Other Accumulated Expenses came in at $4.8 million for Q1 2026 at Assertio Holdings, roughly flat from $4.9 million in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $32.2 million in Q1 2022 to a low of $256000.0 in Q2 2023.
- The 5-year median for Other Accumulated Expenses is $4.1 million (2024), against an average of $6.8 million.
- Across the five-year window, Other Accumulated Expenses plunged 98.97% in 2023 and surged 2306.02% in 2025, its largest moves.
- Assertio Holdings' Other Accumulated Expenses stood at $948000.0 in 2022, then gained by 0.63% to $954000.0 in 2023, then jumped by 327.15% to $4.1 million in 2024, then increased by 19.04% to $4.9 million in 2025, then dropped by 0.41% to $4.8 million in 2026.
- The last three Other Accumulated Expenses figures came in at $4.8 million (Q1 2026), $4.9 million (Q4 2025), and $4.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Assertio Holdings | 150.94 Mn | 79.37 Mn | 7.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.83 Mn |
| Dec 31, 2025 | 4.85 Mn |
| Sep 30, 2025 | 4.87 Mn |
| Jun 30, 2025 | 16.00 Mn |
| Mar 31, 2025 | 16.00 Mn |
| Dec 31, 2024 | 4.08 Mn |
| Sep 30, 2024 | 505,000.00 |
| Jun 30, 2024 | 665,000.00 |
| Mar 31, 2024 | 823,000.00 |
| Dec 31, 2023 | 954,000.00 |
| Sep 30, 2023 | 996,000.00 |
| Jun 30, 2023 | 256,000.00 |
| Mar 31, 2023 | 332,000.00 |
| Dec 31, 2022 | 948,000.00 |
| Sep 30, 2022 | 11.25 Mn |
| Jun 30, 2022 | 16.01 Mn |
| Mar 31, 2022 | 32.16 Mn |
| Dec 31, 2021 | 34.30 Mn |
| Sep 30, 2021 | 11.55 Mn |
| Jun 30, 2021 | 11.64 Mn |